Insider Transactions in Q3 2025 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 30
2025
|
Eric Venker President & Immunovant CEO |
BUY
Grant, award, or other acquisition
|
Direct |
198,413
+10.67%
|
-
|
|
Jul 30
2025
|
Frank Torti President and Vant Chair |
BUY
Grant, award, or other acquisition
|
Direct |
13,736,547
+48.21%
|
-
|
|
Jul 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-0.48%
|
$21,109
$11.35 P/Share
|
|
Jul 21
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
100,000
-6.4%
|
$1,100,000
$11.52 P/Share
|
|
Jul 21
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+6.02%
|
$300,000
$3.85 P/Share
|
|
Jul 17
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,609
+3.61%
|
-
|
|
Jul 17
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
241
-0.25%
|
$2,651
$11.65 P/Share
|
|
Jul 17
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,201
+1.22%
|
-
|